P98 Efficacy and safety of 4 years of continuous ozanimod treatment: an interim analysis of the true north open-label extension study
Why this work is in the frame
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
Bibliographic record
Abstract
<h3>Introduction</h3> The phase 3 True North (TN) study (NCT02435992) demonstrated the efficacy and safety of ozanimod (OZA) over 52 wk in patients (pts) with moderately to severely active ulcerative colitis (UC). This interim analysis of the ongoing TN open-label extension (OLE; NCT02531126) assessed pts with up to ~4 y of OZA treatment. <h3>Methods</h3> Pts in clinical response at Week (W) 52 of OZA treatment during TN who subsequently entered the OLE were analyzed up to OLE W142, representing up to ~4 y of continuous OZA treatment. Symptomatic response and symptomatic remission were evaluated from OLE W5 through OLE W142. Clinical remission, clinical response, endoscopic improvement, and corticosteroid (CS)-free remission were evaluated at OLE W46, W94, and W142. Adverse events were monitored throughout TN and the OLE. <h3>Results</h3> In all, 131 pts entered the OLE after achieving clinical response on OZA at TN W52. At data cutoff, 64.1% completed OLE W142. Symptomatic response and symptomatic remission were observed in 100.0% and 84.4% of pts, respectively, at OLE W5 in observed case (OC) analyses (93.1% and 78.6%, respectively, in nonresponder imputation [NRI] analyses). By OLE W142, symptomatic response and symptomatic remission rates were 98.7% and 88.3%, respectively, in OC analyses (58.0% and 51.9%, respectively, in NRI analyses). Clinical and endoscopic endpoints are shown in figure 1. Of note, 65.3% of TN W52 clinical responders achieved clinical remission and CS-free remission at OLE W142 (OC analyses; 35.9% in NRI analyses). In the last year of follow-up in the OLE, there were no new bradycardia, third-degree atrioventricular block, hypertension, herpes zoster, or macular edema cases, and no clinically meaningful change in malignancy rates. No serious hepatic events occurred. <h3>Conclusions</h3> Clinical responders after 1 y on OZA sustained response for an additional 3 y and achieved clinical remission with continuous OZA exposure. OZA is a well-tolerated, durable therapy for pts with UC.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.000 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.000 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it